Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2019 - 2030

Purchase Option

$ 4400
$ 4000
$ 6000

Idiopathic pulmonary fibrosis primarily occurs in older adults and the disease confined to lungs only. Symptoms may include weight loss, pneumonia, fatigue, low-gradefevers and others. Idiopathic pulmonary fibrosis diagnosis is done through imaging techniques, lung biopsy,laboratory tests and others. Currently, no medications are proven to effectively treat idiopathic pulmonary fibrosis. Generally, Azathioprine, Prednisone,and N-acetyl cysteine are used alone or combination for the treatment.


Key developments: 

Many of the research studies and ongoing trials are studying the various drugs and lead molecules to treat the idiopathic pulmonary fibrosis. The recognition of new factors contributing to the pathogenesis of idiopathic pulmonary fibrosis has led to the development of novel approaches to treat idiopathic pulmonary fibrosis.

  • In August 2017, FibroGen, Inc. announced positive topline results from the companys Phase 2 randomized, double-blind, placebo-controlled study and two combination safety sub-studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF).
  • In October 2017, Prometic Life Sciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBI-4050, a clinical candidate in development for idiopathic pulmonary fibrosis (IPF).


Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment Segmentation

Route of Administration
  • Inhalation
  • Parenteral
  • Others
By Trial Phase
  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Idiopathic Pulmonary Fibrosis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Idiopathic Pulmonary Fibrosis disease pipeline drugs development. This report studies the dynamics of the Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs i.e. drivers, challenges,and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Idiopathic Pulmonary Fibrosis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.



  • Johnson & Johnson Services, Inc. (U.S.)
  • ImmuneWorks, Inc. (U.S.)
  • Hoffmann-La Roche AG (Switzerland)
  • Celgene Corporation (U.S.)
  • Biogen, Inc. (U.S.)
  • FibroGen (U.S.)
  • Bristol-Myers Squibb (U.S.)
  • Promedior, Inc. (U.S)

Adjacent Markets